ArticleSchizophrenia bulletin2026
Practical Approach to Hormone Replacement Therapy for (Peri) Menopausal Women With Schizophrenia Spectrum Disorders: A Case Series.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and hypothesisEstrogens play a neuroprotective role in schizophrenia spectrum disorders (SSD), and evidence suggests that perimenopausal estrogen decline is associated with symptom exacerbation and increased relapse risk in women with SSD. Hormone replacement therapy (HRT) may mitigate these effects, but clinical and epidemiological data on its use in women with SSD remain limited. STUDY
designWe conducted a case series of 5 women (aged 47-53 years) with SSD in perimenopause or postmenopause, who were treated with individualized HRT regimens (transdermal or oral estradiol with oral, vaginal, or intrauterine progestogens) in a psychosis outpatient clinic. The women were monitored for 3 months for psychiatric stability, tolerability, side effects, and menopausal symptoms, using clinical observation and self-report. STUDY
resultsAll 5 women tolerated HRT well, with no serious adverse effects. Three women reported notable improvements in mood, energy, and social functioning. Negative symptoms improved in 4 women, and 1 woman with active positive symptoms experienced partial symptom reduction. Three women reported relief of menopausal symptoms (eg, sleep disturbance, vasomotor symptoms, and joint pain), which was perceived as beneficial to mental stability. All patients continued HRT beyond follow-up.
conclusionsHormone replacement therapy appears feasible and acceptable for women with SSD before and after the menopausal transition, with potential benefits for mood and functional improvement and high tolerability. Individualized approaches and safety considerations are essential. This approach may be integrated into routine psychiatric care, though larger studies with standardized outcomes are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.